{"resolution": {"@star-print": "no-star-print", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "@display": "yes", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. RES. 709"}, "official-title": {"#tail": "\n\t", "quote": {"#tail": " in biotechnology and life sciences funding that stifles innovation and impedes translational\n\t\t\t medical research.", "#text": "Valley of Death"}, "@display": "yes", "#text": "Recognizing the importance of transformative breakthroughs in biomedicine, biotechnology, and life\n\t\t\t sciences in the diagnosis, management, curing, and treatment of illness\n\t\t\t and the existence of a "}, "session": {"#tail": "\n\t\t", "@display": "yes", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "IV"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20140731", "#text": "July 31, 2014"}, "#tail": "\n\t\t", "@display": "yes", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Vargas", "@name-id": "V000130"}, "cosponsor": [{"#tail": ", ", "#text": "Mr. Rodney Davis of Illinois", "@name-id": "D000619"}, {"#tail": ", ", "#text": "Mr. Denham", "@name-id": "D000612"}, {"#tail": ", ", "#text": "Mr. Honda", "@name-id": "H001034"}, {"#tail": ", and ", "#text": "Mr. Rush", "@name-id": "R000515"}, {"#tail": ") submitted the following resolution; which was referred to the ", "#text": "Ms. Matsui", "@name-id": "M001163"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "RESOLUTION"}}, "@resolution-stage": "Introduced-in-House", "@resolution-type": "house-resolution", "resolution-body": {"#tail": "\n", "@style": "traditional", "section": {"@section-type": "undesignated-section", "#tail": "\n  ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "House of Representatives", "@entity-id": "0050"}, "#text": "That the "}, "enum": {"#tail": "\n      "}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "recognizes the importance of transformative breakthroughs in biomedicine, biotechnology, and life\n\t\t\t sciences in the diagnosis, management, curing, and treatment of illness;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H2CC08D661CD2414BB6F392B9996267B6", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": ") in order to\n\t\t\t facilitate expeditious approval of safe and effective new products, better\n\t\t\t outcomes for patients, and more efficient and effective uses of ", "@entity-type": "federal-body", "#text": "FDA", "@entity-id": "7524"}, {"#tail": "\n\t\t\t limited resources;", "@entity-type": "federal-body", "#text": "FDA\u2019s", "@entity-id": "7524"}], "#text": "recognizes the need for bipartisan reform of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "HDB266D5B990D45CB88119D40F8636E22", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "quote": {"#tail": " in biomedicine, biotechnology, and life sciences\n\t\t\t funding, a steadily widening funding and resource gap that currently\n\t\t\t exists between basic research and clinical development, effectively\n\t\t\t limiting the field of potential novel therapies and drugs for patients;\n\t\t\t and", "#text": "Valley of Death"}, "#text": "recognizes the existence of a "}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "H8503A2215BCC49239C32FAC895236EDF", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "recognizes innovative financial structures can achieve the necessary grand scale of capital needed\n\t\t\t to support translational research and development in biomedicine,\n\t\t\t biotechnology, and life sciences."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "H45B1A38C9ACF479A8C28CB396D23EE9D", "#text": "\n        "}], "@display-inline": "yes-display-inline", "#text": "\n      ", "@id": "HB6C5481871F24C49BCB5FE9B93706F09"}, "#text": "\n\t\t", "@id": "HDA1566AA6109421E95B6EEF44EDC446B"}, "@key": "H", "@dms-id": "HFE7E54C15CD849A7AC7083D2DD022B27", "@public-private": "public", "#text": "\n\t", "preamble": {"#tail": "\n\t", "whereas": [{"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas cancer, rare and orphan diseases, diabetes, and Alzheimer\u2019s are just a few of a growing\n\t\t\t number of large-scale challenges confronting modern society that can be\n\t\t\t addressed only through the sustained collaboration of thousands of highly\n\t\t\t skilled, dedicated, and independent individuals over many years;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas many promising breakthroughs have occurred in biomedicine in recent years, including gene\n\t\t\t therapies, molecularly targeted drugs, new modes of medical imaging and\n\t\t\t radiosurgery, biomarkers for drug response, human genome sequencing, and\n\t\t\t advances in bioinformatics that enabled many of these new applications;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas biomedicine is far more advanced today than even a decade ago is indisputable, but\n\t\t\t breakthroughs require years of translational research at a cost of\n\t\t\t hundreds of millions of dollars and have a substantial likelihood of\n\t\t\t failure;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas the drug development pipeline is laden with unfavorable probabilities;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas for every 5,000 to 10,000 compounds that enter the drug discovery pipeline, just 250\n\t\t\t progress to preclinical development, and only one will become an approved\n\t\t\t drug;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas the aggregate research and development budget of the pharmaceutical industry has nearly\n\t\t\t doubled from $68,000,000,000 in 2002 to $127,000,000,000 in 2010, there\n\t\t\t has been little appreciable impact on the number of new drugs approved;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " must work in a bipartisan fashion to reform the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": "\n\t\t\t (", "@entity-type": "federal-body", "#text": "Food and Drug Administration\u2019s", "@entity-id": "7524"}, {"#tail": ") review process for drug development and biomedical innovation in\n\t\t\t order to facilitate expeditious approval of safe and effective new\n\t\t\t products, better outcomes for patients, and more efficient and effective\n\t\t\t uses of ", "@entity-type": "federal-body", "#text": "FDA", "@entity-id": "7524"}, {"#tail": " limited resources;", "@entity-type": "federal-body", "#text": "FDA\u2019s", "@entity-id": "7524"}], "#text": "Whereas "}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas biomedical innovation has become much more challenging to finance with private and public\n\t\t\t equity;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas there is a growing concern within and outside the industry that the process of translating\n\t\t\t biomedical research into effective treatments is obsolete;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas biotech and life sciences traditional financing vehicles of private and public equity are\n\t\t\t becoming less effective funding sources because the needs and expectations\n\t\t\t of limited partners and shareholders are not consistent with the\n\t\t\t increasing complexity and risk of biomedical innovation;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas the lengthy process of biomedical innovation is becoming increasingly complex, expensive,\n\t\t\t uncertain, and fraught with conflicting motivations and public-policy\n\t\t\t implications;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"#tail": ", a steadily widening\n\t\t\t funding and resource gap that currently exists between basic research and\n\t\t\t clinical development, effectively limiting the field of potential novel\n\t\t\t therapies, technologies, and treatments for patients;", "#text": "Valley of Death"}, "#text": "Whereas industry professionals frequently refer to the "}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas the life sciences industry needs novel approaches to early-stage drug development that\n\t\t\t better manage risk, lower capital cost, improve research effectiveness,\n\t\t\t create diverse portfolios, leverage risk-tolerant capital, and access new\n\t\t\t capital sources; and"}, "#text": "\n      "}, {"#tail": "\n  ", "text": {"#tail": "\n    ", "#text": "Whereas innovative financial structures can achieve the necessary grand scale of capital needed to\n\t\t\t support effective diversification of biotech investments and create stable\n\t\t\t and attractive investment opportunities along the development pipeline:\n\t\t\t Now, therefore, be it"}, "#text": "\n      "}], "#text": "\n\t\t"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-07-31"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HRES 709 IH: Recognizing the importance of transformative breakthroughs in biomedicine, biotechnology, and life sciences in the diagnosis, management, curing, and treatment of illness and the existence of a \u201cValley of Death\u201d in biotechnology and life sciences funding that stifles innovation and impedes translational medical research."}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}